Three months into the COVID-19 outbreak caused by a novel strain of coronavirus (SARS-CoV-2), the world is still in search of an effective therapeutic drug. Experimental drugs developed for other infections, such as Gilead's remdesivir, have been repurposed with unclear success. A recent small...

Nursing homes have been caught in the crosshairs of the coronavirus pandemic. As of early May 2020, Covid-19 had claimed the lives of more than 28,000 nursing home residents and staff in the United States. But U.S. nursing homes were unstable even before Covid-19 hit. The tragedy unfolding in...

America’s COVID-19 pandemic has both devastated and disparately harmed minority communities. How can the allocation of scarce treatments for COVID-19 and similar public health threats fairly and legally respond to these racial disparities? Some have proposed that members of racial groups who...

This paper compares drivers of full COVID-19 vaccinations and booster doses across U.S. counties. Booster doses are contingent upon someone receiving the primary doses, and the risk attitudes and propensities to get vaccinated may be different across individuals, along with the supply chain...

The portfolio approach of financing drug development has been proposed as a financial innovation to improve the risk/return tradeoff of investment in drug development projects through the use of diversification and securitization. By investing in a sizable and well-diversified portfolio of novel...

This paper studies the propensities of the U.S. population to seek a full dose of vaccinations against the COVID-19 pandemic. Beyond the consideration of vaccine dissemination at the disaggregated or the local level, the main focus of this study is on determining whether a lack of health...

The COVID-19 pandemic has highlighted problems regarding scarcity of lifesaving medicines. During pandemics and epidemics, a sudden surge in demand for medicines is often unmatched on the supply side. Moreover, the same intellectual property rights that are supposed to incentivize their creation...

This paper examines the impact of the local opioid epidemic on corporate innovation. Using a large sample of U.S. public firms from 2003 to 2017, we find that firms located in counties with higher death rates caused by opioid overdoses are significantly less innovative as measured by their...